GlassScriptPhysician profile
Stephanie Slough
NPI 1124539895
$3,729.23
in general payments reported to CMS, 2019-2025
39 companies · $794 in 2025
The $794 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $696 · 2022: $734 · 2023: $817 · 2024: $689 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $439.51 | 2021-2025 | Breztri, Airsupra, Lokelma |
| Teva Pharmaceuticals USA, INC. | $405.34 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $368.36 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $236.23 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $219.76 | 2021-2023 | |
| Amgen INC. | $172.15 | 2021-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.58 | 2022-2025 | Caplyta |
| Pfizer INC. | $150.08 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $109.64 | 2021-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $109.35 | 2021-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.41 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $65.63 | 2022 | |
| Sunovion Pharmaceuticals INC. | $59.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $57.63 | 2021-2023 | Xarelto |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $56.75 | 2023-2025 | Veozah |
| Biogen, INC. | $53.33 | 2021 | |
| Exact Sciences Corporation | $51.34 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $44.28 | 2023-2024 | Qelbree, Qelbree |
| Abiomed | $38.62 | 2025 | |
| Sk Life Science, INC. | $36.70 | 2024-2025 | |
| Corium, LLC | $31.66 | 2023 | Adlarity |
| Kyowa Kirin, INC. | $27.59 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.51 | 2023 | |
| Genentech USA, INC. | $22.33 | 2021 | |
| Lundbeck LLC | $22.04 | 2025 | Rexulti |
| Alk-Abello, INC | $21.39 | 2024 | Odactra, Grastek, Ragwitek |
| Viatris Specialty LLC | $20.09 | 2025 | Yupelri |
| Indivior INC. | $19.93 | 2024 | Perseris |
| Abbott Laboratories | $19.85 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.91 | 2022 | |
| Sumitomo Pharma America, INC. | $18.38 | 2023 | Gemtesa, Aptiom |
| Eisai INC. | $17.99 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.11 | 2025 | Gvoke Hypopen |
| Inogen, INC. | $15.91 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.88 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.05 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Slough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.